Get the Daily Brief
Latest Biotech News
Next‑gen cell engineering: Multiplex epigenetic editing and novel CAR T candidates
A Nature Biotechnology paper introduced an epigenetic editing platform enabling safe, multiplexed gene programming in primary human T cells to enhance CAR‑T potency and manufacturability. The...
Series C and pre‑seed rounds: Step and Cyclana fund next programs
Step Pharma closed a €38 million Series C to advance its CTPS1 inhibitor dencatistat across multiple hematologic and solid tumor studies, financing trials across lymphomas and solid tumors and...
Sanofi bets >$500M on Evoq’s NanoDisc: Autoimmunity pact sealed
Sanofi signed a collaboration and licensing agreement with Evoq Therapeutics that could deliver more than $500 million in milestone payments tied to preclinical, development and sales goals. Evoq...
10x Genomics sues Illumina: Patent fight escalates in sequencing wars
10x Genomics filed patent infringement lawsuits against Illumina in Delaware federal court, accusing the sequencing giant of using its patented single-cell and spatial genomics technologies to...
Grail secures $325M ahead of FDA push — cash to fund commercial scale-up
Grail raised approximately $325 million in a private placement to bolster commercial activities, reimbursement efforts and working capital as the company prepares regulatory filings and market...
FDA accepts Replimune resubmission — second review set, stock surges
The U.S. Food and Drug Administration accepted Replimune’s resubmitted biologics license application for RP1, an oncolytic herpesvirus engineered to prime immune responses, and set a target...
Galapagos to exit cell therapy — unit fails to find buyer, layoffs expected
Galapagos announced plans to wind down its cell therapy program after an active divestment process failed to surface acceptable buyers. Non-binding offers were reportedly dominated by financial...
Exelixis readout fuels NDA plan — zanzalintinib + atezolizumab heads to regulators
Exelixis reported detailed STELLAR‑303 data showing its oral TKI zanzalintinib plus atezolizumab reduced risk of death vs. regorafenib in previously treated metastatic colorectal cancer, and the...
ctDNA steers adjuvant care at ESMO — Roche’s Tecentriq data and broader trials
Data presented at ESMO strengthened the case for circulating tumor DNA (ctDNA) to guide adjuvant treatment decisions. Roche reported a phase 3 analysis showing adjuvant atezolizumab provided a...
Novo board overhaul: Controlling shareholder reclaims operational focus
Novo’s largest shareholder moved to reshape the company’s board, prompting resignation of multiple independent directors and signaling a shift toward tighter operational oversight amid investor...
PCSK9’s second act: Antibodies, editing and a Verve buy that rewrites playbook
PCSK9 — long a validated target for cholesterol lowering via monoclonal antibodies and siRNA — is reemerging as a focal point for gene‑editing strategies after Eli Lilly’s acquisition of Verve...
T‑cell expansion signature could predict immunotherapy response — single‑cell TCR work
Researchers at Tokyo University of Science published a pan‑immunotherapy gene signature that predicts intratumoral CD8+ T‑cell clonal expansion, using multi‑site tumor mouse models and...
Novo main backer forces boardroom purge — chair to step down
The Novo Nordisk shareholder behind the company’s foundation has pushed out more than half of the drugmaker’s board, triggering an executive shake-up at the maker of obesity drug Wegovy. The move...
10x sues Illumina: patent fight targets single-cell expansion
10x Genomics filed two patent lawsuits against Illumina alleging infringement tied to sequencing and single-cell/spatial technologies as it seeks to broaden its product portfolio. The complaints,...
Grail pulls $325M — bankroll to support commercialization and FDA push
Grail secured about $325 million in a private placement to fund commercial expansion, reimbursement efforts and its planned regulatory push for multi-cancer early detection tests. The financing...
FDA accepts Replimune resubmission — review clock set for April
Replimune announced that the U.S. FDA has accepted its resubmitted biologics license application for RP1 in advanced melanoma and set a target decision date of April 10, 2026. The filing adds...
Exelixis to file NDA after Phase 3 OS win — colorectal combo trims mortality
Exelixis said detailed STELLAR-303 results show its oral TKI zanzalintinib combined with Roche’s Tecentriq reduced risk of death by about 20% versus standard therapy in previously treated...
AI arms race in life sciences... new models and lab partnerships accelerate discovery
Anthropic launched a life-sciences–focused model and inked collaborations to let researchers query biological datasets in plain English, signaling Big Tech’s deeper push into drug discovery and...
CDMOs take center stage — capacity and capability strain in cell & gene era
Industry analysis and company moves underscore a pivot: contract development and manufacturing organizations (CDMOs) are now strategic partners for cell and gene therapy scale-up. Reports stress...
Single-cell signature predicts CD8+ T cell bursts — a potential biomarker for immunotherapy
Researchers using single-cell RNA and TCR sequencing in longitudinal mouse tumor models identified a conserved gene expression 'expansion signature' that predicts CD8+ T cell clonal bursts prior...